Latest Period
Q1 2026
Security Snapshot
INTENSITY THERAPEUTICS, INC. - Common Stock, $0.0001 par value (INTS) Institutional Ownership
CUSIP: 45828J103
13F Institutional Holders and Ownership History from Q2 2023 to Q1 2026
Institutions Reporting
0
Shares (Excl. Options)
0
Price
$0.22
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock, $0.0001 par value
- Symbol
- INTS on Nasdaq
- Shares outstanding
- 48,324,727
- Price per share
- $0.22
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 0
- Total reported value
- $0
- Share change
- -3,239,314
- Value change
- -$1,305,397
- Number of holders
- 0
- Price from insider filings
- $0.22
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- INTS - INTENSITY THERAPEUTICS, INC. - Common Stock, $0.0001 par value is tracked under CUSIP 45828J103.
- 0 institutions reported positions in Q1 2026.
- 2 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 35 to 0 between Q4 2025 and Q1 2026.
- Reported value moved from $1,584,078 to $0.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 0 institutions filings for Q1 2026.
Investment Quick Answers
What is CUSIP 45828J103?
CUSIP 45828J103 identifies INTS - INTENSITY THERAPEUTICS, INC. - Common Stock, $0.0001 par value in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q1 2026 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 45828J103:
Significant Owners of INTENSITY THERAPEUTICS, INC. - Common Stock, $0.0001 par value (INTS) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| ARMISTICE CAPITAL, LLC | 2.6% | -53% | $383,505 | +$113,015 | 1,237,113 | +42% | Armistice Capital, LLC | 30 Jun 2025 |
| SAPIENT CAPITAL LLC | 3.9% | -50% | $312,575 | -$11,287 | 976,797 | -3.5% | SAPIENT CAPITAL LLC | 30 Jun 2025 |
As of 31 Mar 2026, 0 institutional investors reported holding 0 shares of INTENSITY THERAPEUTICS, INC. - Common Stock, $0.0001 par value (INTS). This represents 0% of the company’s total 48,324,727 outstanding shares.
Institutional Holders of INTENSITY THERAPEUTICS, INC. - Common Stock, $0.0001 par value (INTS) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 0 | $0 | -$1,305,397 | $0.22 | 0 |
| 2025 Q4 | 3,919,007 | $1,584,078 | +$402,573 | $0.41 | 35 |
| 2025 Q3 | 2,961,433 | $721,188 | +$231,320 | $0.24 | 26 |
| 2025 Q2 | 1,978,698 | $606,612 | -$1,718,334 | $0.31 | 27 |
| 2025 Q1 | 2,588,459 | $5,099,279 | -$255,643 | $1.97 | 21 |
| 2024 Q4 | 2,720,161 | $4,790,715 | +$1,642,568 | $1.76 | 20 |
| 2024 Q3 | 1,740,070 | $6,647,274 | +$185,658 | $3.82 | 20 |
| 2024 Q2 | 1,678,720 | $8,230,325 | +$224,021 | $4.90 | 22 |
| 2024 Q1 | 1,632,608 | $8,490,357 | +$5,402,744 | $5.20 | 17 |
| 2023 Q4 | 512,614 | $4,392,713 | +$236,954 | $8.57 | 16 |
| 2023 Q3 | 298,447 | $1,190,347 | +$1,020,510 | $3.97 | 10 |
| 2023 Q2 | 28,563 | $170,235 | +$170,235 | $5.96 | 2 |